Veloxis CEO expects to close partnership deals this year

The sale of Veloxis’ lead product Envarsus XR is still relatively modest, but plans to enter into a slew of distribution deals should give a much needed growth boost in 2017, while new appointments should also push growth and aid the Danish company’s contact with the US FDA.

Foto: Colourbox

The US launch of Veloxis’ drug Envarsus XR, used to prevent organ rejection in transplantees, helped the company to quadruple revenue in 2016. It gives the management team, led by CEO Craig Collard, cause for optimism for 2017.

“It has been a bit of a transition year for Veloxis. I joined the company in December 2015, and since then we have replaced the entire management team and restructured the organization. In the middle of all that, we have also launched Envarsus XR in the US. So a lot has happened, but I feel like the business is slowly accelerating,” Craig Collard says in an interview with MedWatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier